A new animal model for assessing mechanisms and management of muscle hyperalgesia
- 1 April 2000
- journal article
- Published by Wolters Kluwer Health in PAIN®
- Vol. 85 (3) , 333-343
- https://doi.org/10.1016/s0304-3959(99)00282-1
Abstract
Musculoskeletal pain is one of the most frequent symptoms for which medical assistance is sought. Yet, the majority of our knowledge regarding pain physiology is based on studies of cutaneous tissue. Comparatively little is known about activation of visceral, joint and perhaps least of all, musculoskeletal nociceptors although clinically-treated pain originates principally in these structures. Studies elucidating the mechanisms of muscle hyperalgesia have been hampered by the lack of an animal model that permits the evaluation of hypotheses using behavioral, biochemical, pharmacological, anatomical and molecular experimental approaches. Here we describe an animal model of muscle hyperalgesia we recently developed that permits such multidisciplinary investigation. This model employs the intramuscular injection of carrageenan, a chemical stimulus which evokes a well recognized model of cutaneous inflammation and is reported to activate muscle nociceptors. Intramuscular carrageenan evokes a time- and dose-dependent reduction in forelimb grip force that is anatomically specific. The carrageenan-evoked reduction in grip force is blocked by the μ-opioid agonist levorphanol in a dose-dependent, stereoselective and naltrexone-reversible manner. This behavioral dependent measure is also significantly reversed by agents used clinically to treat muscle pain, indomethacin and dexamethasone, as well as the non-competitive N-methyl-D-aspartate receptor antagonist MK801. Finally, evidence that reduction in grip force is in part mediated by small, unmyelinated afferents is provided by the demonstration that neonatal capsaicin treatment significantly reduced carrageenan-evoked behavioral hyperalgesia (˜45% reduction) and reduced muscle content of immunoreactive CGRP (˜60% reduction) relative to control levels. Collectively, these findings provide converging lines of evidence for the validity of this animal model to investigate mechanisms involved in the development of muscle hyperalgesia.Keywords
This publication has 46 references indexed in Scilit:
- Grip Force in Patients with Rheumatoid Arthritis and Fibromyalgia and in Healthy Subjects. A Study with the Grippit InstrumentScandinavian Journal of Rheumatology, 1993
- The effects of a non-competitive NMDA receptor antagonist, MK-801, on behavioral hyperalgesia and dorsal horn neuronal activity in rats with unilateral inflammationPain, 1992
- Developmental alterations in nociceptive threshold, immunoreactive calcitonin gene‐related peptide and substance P, and fluoride‐resistant acid phosphatase in neonatally capsaicin‐treated ratsJournal of Comparative Neurology, 1991
- Peripheral patterns of calcitonin‐gene‐related peptide general somatic sensory innervation: Cutaneous and deep terminationsJournal of Comparative Neurology, 1989
- Histological and neurophysiological changes induced by carrageenan in skeletal muscle of cat and ratInflammation Research, 1988
- A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesiaPAIN®, 1988
- Opioid Analgesia at Peripheral SitesAnesthesia & Analgesia, 1987
- Effect of Calcitonin Gene-Related Peptide on the Cyclic AMP Level of Isolated Mouse DiaphragmThe Japanese Journal of Pharmacology, 1986
- Effect of calcitonin gene-related peptide on contraction of striated muscle in the mouseNeuroscience Letters, 1985
- Studies of the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentineThe Journal of Pathology, 1971